Cost-Effectiveness of First-Line Tyrosine Kinase Inhibitor Therapy Initiation Strategies for Chronic Myeloid Leukemia

Dec 1, 2020, 00:00
10.1016/j.jval.2020.10.007
https://www.valueinhealthjournal.com/article/S1098-3015(20)34450-8/fulltext
Title : Cost-Effectiveness of First-Line Tyrosine Kinase Inhibitor Therapy Initiation Strategies for Chronic Myeloid Leukemia
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(20)34450-8&doi=10.1016/j.jval.2020.10.007
First page : 1671
Section Title : CORRECTIONS
Open access? : No
Section Order : 1671
Value Health. 2020;23(10):1292-1299.
DOI of original article: https://doi.org/10.1016/j.jval.2020.05.019
Portions of the Article and Author Information section (namely the author contributions, conflict of interest disclosures, funding/support, role of funder, and acknowledgement statements) that were published with this paper were for a different article. This article appears correctly online.
Categories :
  • Clinical Outcomes
  • Clinical Outcomes Assessment
  • Cost-comparison, Effectiveness, Utility, Benefit Analysis
  • Economic Evaluation
  • Health Service Delivery & Process of Care
  • Oncology
  • Specific Diseases & Conditions
  • Treatment Patterns and Guidelines
Tags :
Regions :
ViH Article Tags :